Brokerages Set 10x Genomics, Inc. (NASDAQ:TXG) PT at $29.19

10x Genomics, Inc. (NASDAQ:TXG - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the seventeen ratings firms that are currently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell rating, seven have given a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $29.19.

A number of equities research analysts have issued reports on TXG shares. Canaccord Genuity Group decreased their price target on shares of 10x Genomics from $32.00 to $20.00 and set a "buy" rating for the company in a report on Thursday, October 10th. Barclays decreased their target price on 10x Genomics from $21.00 to $19.00 and set an "overweight" rating for the company in a research note on Friday, November 1st. JPMorgan Chase & Co. dropped their price target on 10x Genomics from $20.00 to $14.00 and set a "neutral" rating on the stock in a research report on Wednesday, October 30th. Leerink Partnrs upgraded 10x Genomics to a "strong-buy" rating in a report on Tuesday, September 3rd. Finally, Stephens restated an "overweight" rating and issued a $30.00 price objective on shares of 10x Genomics in a research note on Thursday, October 10th.

Institutional Trading of 10x Genomics

Several institutional investors have recently bought and sold shares of the stock. Geode Capital Management LLC lifted its holdings in 10x Genomics by 2.4% during the 3rd quarter. Geode Capital Management LLC now owns 1,815,710 shares of the company's stock valued at $41,009,000 after purchasing an additional 42,777 shares during the last quarter. M&T Bank Corp acquired a new stake in shares of 10x Genomics during the third quarter worth approximately $203,000. Barclays PLC raised its stake in shares of 10x Genomics by 11.7% in the third quarter. Barclays PLC now owns 602,536 shares of the company's stock valued at $13,605,000 after acquiring an additional 63,079 shares during the last quarter. Y Intercept Hong Kong Ltd acquired a new position in shares of 10x Genomics in the 3rd quarter worth approximately $402,000. Finally, XTX Topco Ltd grew its position in 10x Genomics by 241.9% during the 3rd quarter. XTX Topco Ltd now owns 45,008 shares of the company's stock worth $1,016,000 after acquiring an additional 31,844 shares during the last quarter. Institutional investors and hedge funds own 84.68% of the company's stock.

10x Genomics Trading Up 4.2 %

NASDAQ TXG traded up $0.64 during trading on Friday, reaching $15.87. 1,149,943 shares of the company's stock were exchanged, compared to its average volume of 1,742,373. 10x Genomics has a fifty-two week low of $12.95 and a fifty-two week high of $57.90. The company's fifty day simple moving average is $16.38 and its 200-day simple moving average is $19.32. The firm has a market capitalization of $1.92 billion, a PE ratio of -9.95 and a beta of 1.84.

10x Genomics (NASDAQ:TXG - Get Free Report) last posted its quarterly earnings results on Tuesday, October 29th. The company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.34) by $0.04. The business had revenue of $151.65 million during the quarter, compared to analysts' expectations of $158.84 million. 10x Genomics had a negative net margin of 28.93% and a negative return on equity of 25.07%. The firm's quarterly revenue was down 1.3% compared to the same quarter last year. During the same period last year, the company posted ($0.51) earnings per share. Equities analysts forecast that 10x Genomics will post -1.4 EPS for the current fiscal year.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.